BRIEF published on 01/27/2026 at 18:05, 5 days 5 hours ago Theranexus Liquidity Contract Half-Year Review Liquidity Contract PORTZAMPARC Financial Report Theranexus THX Pharma Actions
BRIEF published on 01/20/2026 at 18:05, 12 days 5 hours ago THX Pharma unveils its 2026 financial calendar Euronext Paris Financial Agenda Biopharmaceutical 2026 THX Pharma
BRIEF published on 01/20/2026 at 18:05, 12 days 5 hours ago THX Pharma Reveals 2026 Financial Schedule Financial Calendar Neurological Diseases Market Communication 2026 Announcements THX Pharma
PRESS RELEASE published on 01/20/2026 at 18:00, 12 days 5 hours ago THX Pharma Announces its 2026 Financial Calendar THX Pharma (Theranexus) announces financial communication agenda for 2026, focusing on rare neurological diseases treatments. Company listed on Euronext Growth Paris Euronext Growth Paris Financial Communication Theranexus Neurological Diseases THX Pharma
BRIEF published on 01/08/2026 at 18:05, 24 days 5 hours ago THX Pharma Releases Shareholder Letter Drug Development Biopharmaceutical Shareholder Communication Neurological Diseases THX Pharma
BRIEF published on 01/08/2026 at 18:05, 24 days 5 hours ago Publication of the letter to shareholders by Theranexus Shareholders Neuroscience Rare Diseases Theranexus Drugs
PRESS RELEASE published on 01/08/2026 at 18:00, 24 days 5 hours ago THX Pharma announces the publication of its letter to shareholders THX Pharma (Theranexus) announces the publication of its letter to shareholders, highlighting treatments for rare neurological diseases and upcoming drug commercialization. Forward-looking statements included Forward-looking Statements Theranexus Neurological Diseases THX Pharma Drug Commercialization
BRIEF published on 01/07/2026 at 08:05, 25 days 15 hours ago THX Pharma Names Julien Veys as Deputy CEO Rare Neurological Diseases THX Pharma Julien Veys Appointment Theranexus Strategy Pharmaceutical Commercialization
BRIEF published on 01/07/2026 at 08:05, 25 days 15 hours ago THX Pharma appoints Julien Veys as Deputy General Manager Business Strategy Appointment THX Pharma Julien Veys Neurological Medications
PRESS RELEASE published on 01/07/2026 at 08:00, 25 days 15 hours ago THX Pharma Announces the Appointment of Julien Veys as Deputy Chief Executive Officer THX Pharma appoints Julien Veys as Deputy CEO to drive new strategy focusing on regulatory approval and commercialization of medicines for rare neurological diseases Regulatory Approval Deputy CEO Neurological Diseases THX Pharma Julien Veys
Published on 01/31/2026 at 03:15, 1 day 19 hours ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 01:40, 1 day 21 hours ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 02/01/2026 at 20:25, 2 hours 47 minutes ago WHO Makes Historic Pivot to County-Level Governance, Validating "Bottom-Up" Climate-Health Model in Tropical Southern China
Published on 01/31/2026 at 15:54, 1 day 7 hours ago EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 1 day 10 hours ago JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 20 hours ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 2 days 1 hour ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 17:45, 2 days 5 hours ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 3 days 5 hours ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 3 days 5 hours ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 3 days 5 hours ago Cegedim generated LFL revenue growth of 1.1% in 2025
